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We performed a genome scan at an average resolution of 8 cM in 719 Finnish sib pairs with type 2 diabetes. Our
strongest results are for chromosome 20, where we observe a weighted maximum LOD score (MLS) of 2.15 at
map position 69.5 cM from pter and secondary weighted LOD-score peaks of 2.04 at 56.5 cM and 1.99 at 17.5
cM. Our next largest MLS is for chromosome 11 (MLS p 1.75 at 84.0 cM), followed by chromosomes 2 (MLS
p 0.87 at 5.5 cM), 10 (MLSp 0.77 at 75.0 cM), and 6 (MLSp 0.61 at 112.5 cM), all under an additive model.
When we condition on chromosome 2 at 8.5 cM, the MLS for chromosome 20 increases to 5.50 at 69.0 cM
( ). An ordered-subsets analysis based on families with high or low diabetes-related quantitative traitsPp .0014
yielded results that support the possible existence of disease-predisposing genes on chromosomes 6 and 10. Ge-
nomewide linkage-disequilibrium analysis using microsatellite marker data revealed strong evidence of association
for D22S423 ( ). Further analyses are being carried out to confirm and to refine the location of thesePp .00007
putative diabetes-predisposing genes.
Introduction
Diabetes is a heterogeneous disorder characterized by a
chronic elevation of plasma glucose. Type 2 diabetes (pre-
viously known as “non–insulin-dependent diabetes mel-
litus” [NIDDM]) accounts for ∼90% of cases, whereas
type 1 diabetes, an autoimmune disorder, explains most
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of the remainder. The metabolic hallmarks of type 2 di-
abetes are insulin resistance, impaired pancreatic beta-cell
function, and increased hepatic glucose production. It is
thought that both genetic and environmental factors con-
tribute to the pathogenesis of type 2 diabetes, but its mode
of inheritance remains unclear (Rich 1990). A rare, mono-
genic form of type 2 diabetes—maturity-onset diabetes of
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the young (MODY)—accounts for ∼1%–5% of type 2
diabetes cases, depending on the population (Shuldiner
and Silver 1996). MODY has an autosomal dominant
mode of inheritance and an earlier age at onset, compared
with most other forms of type 2 diabetes. At least six
different genes have been isolated that independently
cause MODY within single pedigrees (Vionnet et al. 1992;
Yamagata et al. 1996a, 1996b; Horikawa et al. 1997;
Stoffers et al. 1997; Malecki et al. 1999). MODY genes
are thought to play, at most, a minor role in common
type 2 diabetes (Shuldiner and Silver 1996).
There have been numerous studies using the candi-
date-gene approach for type 2 diabetes, but, to date,
none have revealed loci that determine disease in a large
proportion of diabetics (Ghosh and Schork 1996; Kahn
et al. 1996; Elbein 1997). Others have taken a positional
cloning approach, and genome scans for type 2 diabetes
have now been conducted in several samples from dif-
ferent populations (Hanis et al. 1996; Mahtani et al.
1996; Hanson et al. 1998; Duggirala et al. 1999; Elbein
et al. 1999; Ehm et al. 2000). Recently, the chromosome
2 locus linked to type 2 diabetes in Mexican Americans,
also known as “NIDDM1” (Hanis et al. 1996), has been
identified and cloned (Horikawa et al. 2000).
Type 2 diabetes affects nearly 6% of the U.S. and 4%
of the Finnish population 45–64 years of age (Tuomi-
lehto et al. 1991; Bennett et al. 1992; Kenny et al. 1995;
Valle et al. 1997). The Finnish population is believed
to derive largely from a small group of founders, with
little subsequent immigration (Workman et al. 1976),
and has been relatively isolated geographically, linguis-
tically, culturally, and, hence, genetically. Finland also
has comprehensive population and medical databases
that greatly simplify the identification of family mate-
rial, and extensive church records make it possible to
link up families back through several centuries. Finally,
Finland boasts a well-educated population strongly sup-
portive of medical research. These features make Fin-
land an excellent choice for conducting genetic studies.
The FUSION (Finland–United States Investigation of
NIDDM Genetics) study is an international collabora-
tive effort to map and positionally clone genes predis-
posing to type 2 diabetes and intermediate quantitative
traits in Finnish subjects. We have previously under-
taken exclusion mapping for NIDDM1 in our Finnish
sample (Hanis et al. 1996; Ghosh et al. 1998). In ad-
dition, we have reported positive linkage results for
chromosome 20 (Ghosh et al. 1999), giving strong sup-
port to similar results from other groups (Bowden et al.
1997; Ji et al. 1997; Zouali et al. 1997). In the present
article, we describe extended results for chromosome
20 and the entire autosomal genome scan for type 2
diabetes in a carefully ascertained Finnish sample of
affected-sib-pair (ASP) families. In the accompanying
article by Watanabe et al. (2000 [in this issue]), we
analyze important diabetes-related quantitative traits in
affected and unaffected individuals from the same
families.
Subjects and Methods
Subjects
The design of the FUSION study has been described
elsewhere (Valle et al. 1998). In brief, we identified 580
families with an ASP. Index cases were ascertained pri-
marily on the basis of the National Hospital Discharge
Registry, and diabetes was diagnosed according to World
Health Organization (1985) criteria. We selected families
for study using the following rules: (1) 35–60 years as
age at diagnosis of type 2 diabetes in the index case; (2)
at least one living affected sibling; and (3) at least one
parent reported to be unaffected. Our age-at-diagnosis
criterion was chosen to be late enough to exclude most
cases of type 1 diabetes and MODY but early enough
to increase familiality of the disease (Mitchell et al.
1994). In addition, nondiabetic spouses and at least two
unaffected offspring were ascertained in 210 families.
Finally, 231 elderly controls, with two normal oral glu-
cose-tolerance tests documented at ages 65 and 70 years,
were collected. All diabetic subjects had C-peptide and
glutamic acid decarboxylase (GAD) antibody measure-
ments performed, in addition to fasting-insulin and fast-
ing-glucose levels. We also developed criteria based on
fasting C-peptide and GAD levels (Valle et al. 1998) in
addition to insulin-treatment history, to identify affected
siblings with possible late-onset type 1 diabetes. On the
basis of these criteria, 41 families with probable type 1
diabetes were excluded from the present analysis. Family
studies were approved by Institutional Review Boards
at the National Institutes of Health (assurance number
SPA S-5737-05) and at the National Public Health In-
stitute in Helsinki.
Genotyping
DNA samples were isolated from whole blood by a
salting-out procedure (GENTRA DNA isolation kit).
Microsatellite markers with heterozygosities generally
1.7 were chosen from published maps. Genotypes were
determined as described elsewhere (Magnuson et al.
1996; Ghosh et al. 1997). Most of the fluorescently la-
beled microsatellite repeat markers genotyped in this
study were modified from the ABI PRISM Linkage
Mapping Set (PE Biosystems); in addition, some in-
house–designed primer pairs were used (Magnuson et
al. 1996). Single-plex or multiplex PCRs were performed
under cycling conditions of either 3-step  10-min ex-
tension at 72C or a touchdown protocol (Magnuson et
al. 1996; Ghosh et al. 1997, 1998).
1176 Am. J. Hum. Genet. 67:1174–1185, 2000
Statistical Analysis
Map construction and linkage analysis.—We used
RELPAIR (Boehnke and Cox 1997) to detect possible
pedigree errors. We removed cases of non-Mendelian
inheritance, which had been identified by MENDEL
(Lange et al. 1988) through calculation of a zero like-
lihood. Marker order and sex-averaged intermarker dis-
tances were estimated, on the basis of the 210 extended
FUSION families and the CEPH (Centre d’Etude Poly-
morphisme Humaine) reference pedigrees, by maximum
likelihood calculated using CRI-MAP and MultiMap
(Lander and Green 1987; Matise et al. 1994).
For ASP linkage analysis, we employed the mul-
tipoint maximum-likelihood method initially sug-
gested by Risch (1990), as programmed in the com-
puter program SIBLINK (Hauser et al. 1996; Hauser
and Boehnke 1998). This method is parameterized in
terms of the probabilities—z0, z1, and z2—that the ASP
shares, respectively, 0, 1, or 2 genes identical by de-
scent (IBD) at a putative disease-predisposing locus.
We estimated IBD status every 0.5 cM along each
chromosome, using all available marker information
for the chromosome and marker-allele frequencies es-
timated on the basis of our family data. We maximized
the likelihood at each point under either additivity
( ) or the “possible triangle constraints” (Hol-1z p1 2
mans 1993). We performed these analyses twice, first
by treating all pairs as independent and, second, by
weighting the contribution of each ASP by 2/s, where
s is the number of affected sibs in a family (Suarez
and Hodge 1979).
After genotyping had been completed, 61 families
were excluded from the original 580, in addition to the
41 type 1 diabetic families. Of these 61 families, 1 was
removed because of multiple unresolvable pedigree er-
rors. The remaining 60 families were removed because,
after identifiable errors were removed, the families had
no genotyped ASP. From our final analyzed sample of
478 families, we constructed a total of 719 ASPs, ap-
proximately equivalent to 586 ( ) independent sibs 1
pairs (Suarez and Hodge 1979). This comprised 385
families with two, 84 with three, 6 with four, and 1 each
with five, six, and seven affected sibs. In addition, 452
affected sibships had no living parents, 23 had one, and
3 had two.
We present weighted ASP results, recognizing that this
approach is, in general, somewhat conservative (Meu-
nier et al. 1997). Furthermore, only results from the
additive model are described, since the possible-triangle
results are very similar.
Ordered-subsets analysis.—Because of the phenotypic
and likely genotypic heterogeneity underlying type 2 di-
abetes, we performed ordered-subsets analysis (Hauser
et al. 1998). In this analysis, we sought to identify more-
homogeneous groups of families, on the basis of their
mean levels for a diabetes-associated quantitative trait.
For this purpose, we ranked families according to their
mean sibship value for the quantitative trait of inter-
est—for example, body-mass index (BMI). Starting with
the family with the lowest BMI, family-specific LOD
scores were added in, one family at a time, in rank order,
until all families were included. After each family was
added, we determined the MLS for the current subset
of families. The overall MLS obtained for any subset of
the families was finally reported. We then repeated the
analysis, starting with the family with the highest mean
BMI.
We performed this ordered-subsets analysis on the ba-
sis of mean values for fasting glucose, fasting C-peptide,
fasting insulin, SI(EST) (1/[fasting glucose # fasting in-
sulin]), IRI (fasting insulin/fasting glucose), IRC (fasting
C-peptide/fasting glucose), age at diagnosis, and BMI.
The empirical values—SI(EST) for insulin resistance and
IRI and IRC for insulin secretion—were derived to allow
approximate measures of these indices in affected indi-
viduals, since frequently sampled intravenous glucose-
tolerance test analyses were performed only in unaf-
fected relatives (see the accompanying paper by Wa-
tanabe et al. [2000]).
To assess the relationship of pairs of loci in the pre-
disposition to type 2 diabetes, and to identify possible
interactions, we also carried out ordered-subsets analysis
at one locus (the analysis locus), on the basis of evidence
for linkage at another locus (the conditioning locus). In
this case, the covariate for addition of families was the
average, over all ASPs within the family, of the estimated
IBD values at the conditioning locus. Furthermore, we
varied the conditioning point 5 cM around the peak
of the MLS curve on the conditioning chromosome. An
analogous approach to assessment of interaction has re-
cently been described by Cox et al. (1999).
We estimated P values for the ordered-subsets MLS
by using a permutation-test framework (Hauser et al.
1998). Under this permutation framework, the observed
ordered-subsets MLS was compared with the ordered-
subsets MLS obtained at any point along the chromo-
some when families were added in a random order. The
empirical P value was the proportion of 5,000 random
orderings of the families that gave an MLS greater than
the observed ordered-subsets MLS.
Association analysis.—In addition to linkage analysis,
we also carried out linkage-disequilibrium analysis of
our genome-scan data. Although the prior likelihood
that linkage disequilibrium would be identified by use
of a 10-cM map of markers was low, we felt that the
time and expense of gathering the data justified the ef-
fort. In our analysis, we compared the 524 index cases
with a control group comprising the 231 elderly controls
and 162 nondiabetic spouses of either the index cases
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Table 1
Phenotype Descriptions of ASPs with Type 2
Diabetes
Diabetic Index Cases/
Siblings ( )np 1,175
Female:Male Ratio
Sex 599:576
Mean  SD [Median]
Age (years) 64.2  8.3 [64.8]
BMI (kg/m2) 29.8  4.8 [29.3]
WHR .94  .08 [.94]
Fasting glucose (mM) 10.2  3.5 [9.6]
Fasting insulin (pM) 111  67 [96]
Fasting C-peptide (nM) 1.59  .93 [1.44]
SI(EST) (#100) .18  .31 [.11]
IRI 12.0  8.1 [10.3]
IRC .17  .11 [.14]
or their affected siblings. We pooled the latter two
groups after first showing that their allele-frequency dis-
tributions were similar across the markers tested.
Three tests were undertaken for each marker. First,
we calculated a standard Pearson x2 test of association,
using a 2#N table, where N is the number of marker
alleles. Second, in the best-allele test, each marker allele
was compared, in turn, against the pool of all other
marker alleles, and the maximum of these N 2#2 Pear-
son x2 test statistics was taken. This test is tailored to
the situation of a single disease-associated marker allele.
Third, the marker alleles that were more common in
affected individuals were pooled, as were those more
common in unaffected individuals. This high-versus-low
test is aimed at the situation of two or more disease-
associated marker alleles. Each test was performed ini-
tially with all alleles included and then was repeated,
but with the exclusion of alleles present in !10 copies.
We undertook this exclusion to safeguard against the
disproportionate impact of rare alleles on the test sta-
tistics. Significance levels for all three statistics were as-
sessed by permutation, because of the sparse data and
the data manipulation for the best-allele and high-ver-
sus-low tests; we used 100,000 permuted data sets for
this purpose.
Results
Our affected subjects had a nearly equal sex distribution,
were mostly 50–70 years of age (see table 1), and had
been diagnosed with diabetes for a mean period of 12
years at the time of study. A total of 408 microsatellite
markers were typed in this sample, producing an au-
tosomal map of estimated length 3,323 cM, with an
average resolution of ∼8 cM. There were two gaps 120
cM in estimated length: 21.0 cM on chromosome 18,
between markers D18S63 and D18S843, and 24.4 cM
on chromosome 13, between D13S263 and D13S156.
Results for the complete autosomal genome scan, in-
cluding both weighted and unweighted ASP linkage
analysis under the additive model and association anal-
ysis for all three tests of association, are presented in
figures 1 and 2. In what follows, we present results
chosen from among those with ASP MLSs 10.5 and
ordered-subsets analysis MLSs with .P  .05
Chromosome 6 (Fig. 3A)
The MLS was 0.61 at 112.5 cM between markers
D6S287 and D6S262. Ordered-subsets analysis identi-
fied 94 families with the lowest mean fasting plasma
glucose, on the basis of an MLS of 3.17 ( ) atPp .013
117.0 cM. The range for mean plasma glucose in these
sibships was 4.43–8.16 mM. Ordered-subsets analysis
also identified 74 families with lowest mean age at di-
agnosis, on the basis of an MLS of 2.48 ( ) atPp .041
104.5 cM. The range for the mean age at diagnosis was
29–44 years. Eleven families were common to both or-
dered subsets. In this analysis, no evidence for linkage
with the HLA region was detected, suggesting that our
procedure to exclude families with individuals with type
1 diabetes was successful.
Chromosome 10 (Fig. 3B)
MLSs of 0.64 at 54.5 cM (between markers D10S197
and D10S208) and of 0.77 at 75.0 cM (between markers
D10S1652 and D10S537) were obtained. Ordered-sub-
sets analysis identified (a) 40 families with the lowest IRI
(range of mean IRI 0.81–5.27 pmol/mmol), on the basis
of an MLS of 3.12 ( ) at 114.5 cM; (b) 75Pp .015
families with the highest BMI (range of mean BMI
33.7–41.4 kg/m2), on the basis of an MLS of 2.89
( ) at 83.0 cM; and (c) 28 families with thePp .031
highest fasting C-peptide (range of mean 3.06–4.46
nM), on the basis of an MLS of 2.90 ( ) at 76.5Pp .025
cM. There were no families that appeared in all three
ordered subsets. The marker D10S217 at 150.4 cM
showed some evidence of association with diabetes (best
allele ).Pp .0074
Chromosome 11 (Fig. 3C)
The MLS was 1.75 at 84.0 cM, close to D11S901.
The nearby marker D11S1314 at 73.8 cM was weakly
associated with diabetes (best allele ).Pp .042
Chromosome 2 (Fig. 4A)
The MLS was 0.87 at 5.5 cM between markers
D2S319 and D2S162.
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Figure 1 Genomewide single-point association analysis and genomewide weighted and unweighted multipoint linkage analysis for type
2 diabetes, on chromosomes 1–8. In the linkage analysis, results are for the additive analysis. For association, the 2#N, best-allele, and high-
versus-low analyses are shown for each marker.
Chromosome 20 (Fig. 4B)
In a previous article, we reported MLSs of 1.92 (at
18.5 cM), 2.06 (at 57.0 cM), and 2.00 (at 69.5 cM) for
chromosome 20, on the basis of analysis of 38 markers
(Ghosh et al. 1999). With the addition of five more
markers, the up-to-date results are MLS peaks of 1.99
at 17.5 cM, 2.04 at 56.5 cM, and 2.15 at 69.5 cM. The
marker D20S892 at 21.0 cM is associated with diabetes
(high-versus-low ) and is ∼3.5 cM centromer-Pp .0055
ic from the LOD-score peak on the p arm.
Chromosome 20/Chromosome 2 Interaction (Fig. 4B)
In an attempt to increase mapping resolution for chro-
mosome 20, we performed two-locus analysis by car-
rying out ordered-subsets analysis on IBD sharing in
regions suggestive of linkage on chromosomes 2, 7, 10,
and 11. When we placed the conditioning point at 5.5
cM on chromosome 2, the MLS for chromosome 20
increased to 5.06 ( ) at 69.0 cM. To find thePp .007
highest MLS for chromosome 20, we also explored mov-
ing the conditioning point away from 5.5 cM on chro-
mosome 2. When the conditioning point was placed at
8.5 cM on chromosome 2, the MLS increased to 5.50
( ) at 69.0 cM on chromosome 20, with a 1-Pp .0014
LOD support interval of width 7.5 cM, as opposed to
40 cM for unconditional analysis. Data on 273 families
with mean IBD 1.48 at position 8.5 cM on chromosome
2 contributed to this interaction MLS. This was the larg-
est conditional MLS for any of our pairs of linkage
peaks; it also was the largest conditional MLS for any
pair of points along the entire genome.
Chromosome 22
In this genome scan, a marker on chromosome 22
showed the strongest association with diabetes (fig. 2).
A single allele for the marker D22S423 (43.6 cM) was
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Figure 2 Genomewide single-point association analysis and genomewide weighted and unweighted multipoint linkage analysis for type
2 diabetes, on chromosomes 9–22.
present at a frequency of 17.7% in affected individuals
and 10.5% in controls and spouses ( ). How-Pp .00007
ever, there was no evidence for linkage in this region.
Discussion
Genome scans have been completed for type 2 diabetes
and related traits in several populations (Hanis et al.
1996; Mahtani et al. 1996; Stern et al. 1996; Hanson
et al. 1998; Imperatore et al. 1998; Pratley et al. 1998;
Duggirala et al. 1999; Elbein et al. 1999; Ehm et al.
2000). The genome scan reported here for type 2 dia-
betes–susceptibility genes in a Finnish sample represents
one of the largest genetic studies thus far of this complex
metabolic disorder (Valle et al. 1998). We have per-
formed multipoint ASP linkage, ordered-subsets linkage,
and association analyses for type 2 diabetes. The ASP
analysis uses all sibships, whereas the ordered-subsets
analysis is based on selected sibships who have either
the largest or smallest mean values for a diabetes-related
quantitative trait. Ordered-subsets analysis yields a more
homogenous group.
The association analysis comparing probands with
unaffected spouses and elderly controls was used as a
screening tool for possible linkage disequilibrium. We
fully recognize the low prior probability of detecting
disequilibrium for a complex disease in a 10-cM genome
scan, even in a relatively isolated population such as
that of Finland. Our interesting association result with
D22S423 must be interpreted with caution. In the ac-
companying paper by Watanabe et al. (2000 [in this
issue]), we describe QTL analysis of metabolic and an-
thropometric traits, and we report results for both af-
fected and unaffected predisposed family members. We
believe that this sort of multipronged attack is a useful
approach in the dissection of type 2 diabetes or any
complex genetic disease (Ghosh and Schork 1996).
Our LOD scores for the ASP analyses do not reach
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Figure 3 ASP linkage analysis and ordered-subsets–linkage results for type 2 diabetes. A, ASP linkage results for chromosome 6, for all
families, for 94 families with the lowest fasting plasma-glucose levels, and for 74 families with the lowest age at onset. B, ASP linkage results
for chromosome 10, for all families, for 40 families with the lowest IRI, for 75 families with the highest BMI, and for 28 families with the
highest fasting C-peptide. C, ASP linkage results for chromosome 11.
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Figure 4 Interaction-analysis plots for chromosome 20, conditional on chromosome 2. A, ASP linkage results for all families, for chro-
mosome 2. B, ASP linkage results for chromosome 20. There is an increase in LOD score for chromosome 20, to 5.50 at 69.0 cM, when we
condition on chromosome 2 at 8.5 cM.
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genomewide significance according to accepted criteria
(Lander and Kruglyak 1995). It is clear that some of
the results that we report here may well be false posi-
tives. However, our multipronged approach, along with
reports from other groups, gives support to our results.
Our three largest ASP LOD scores are for chromo-
some 20—one on the p arm, one near the centro-
mere, and one on the q arm. The interaction result with
chromosome 2 increases both the evidence for linkage
and the resolution for the locus at 69.5 cM on chro-
mosome 20. In addition, the diabetes-associated marker
D20S892 at 21 cM is close to the MLS peak at 17.5
cM. Three other groups have also reported evidence for
linkage on 20q (Bowden et al. 1997; Ji et al. 1997;
Zouali et al. 1997).
Our next largest MLS is for chromosome 11 at 84.0
cM. Pratley et al. (1998) reported a multipoint MLS
of 1.31 for 2-h insulin levels, very near the marker
D11S2371, in 388 unaffected Pima Indian sib pairs.
Microsatellite mapping data from the Center for Med-
ical Genetics, Marshfield Medical Research Foundation
(Broman et al. 1998), suggest that this peak occurs at
∼76 cM on our map. The candidate genes in this re-
gion include uncoupling protein 2 (MIM 601693) (∼76
cM on our map), pyruvate carboxylase (MIM 266150)
(∼71 cM), and muscle glycogen phosphorylase (MIM
232600) (∼69 cM). The nearby region between
D11S2000 and D11S912 (∼101-137 cM on our map)
has also demonstrated evidence for linkage, in Pima
Indians, to diabetes, BMI (Hanson et al. 1998), per-
centage of body fat (Norman et al. 1997, 1998), and
2-h insulin levels (Pratley et al. 1998).
In our data, there is some evidence for a diabetes gene
on chromosome 6q that affects age at diagnosis (or-
dered-subsets MLSp 2.48 at 104.5 cM). Hanson et al.
(1998) also reported a single-point MLS of 1.84 for
age-adjusted diabetes, at D6S1009 (120.1 cM on our
map) in 264 Pima Indian nuclear families containing
966 siblings. In addition, IDDM15 is located at ∼90
cM on our map (Dele´pine et al. 1997). Since we have
removed sibs who either have or are likely to have type
1 diabetes, this could imply that the same susceptibil-
ity gene influences both forms of diabetes. Stern et al.
(1996) studied 444 individuals from 32 Mexican Amer-
ican families and found an MLS 11 for both fasting and
2-h glucose levels, near D6S292 at 119.5 cM on our
map. Hanis et al. (1996) obtained a single-point MLS
of 0.77 at D6S262 (114.2 cM on our map) in a separate
Mexican American sample.
Our results for chromosome 10 at 75.0 cM suggest
a locus that may be involved in both obesity and dia-
betes. Interestingly, in the accompanying paper (Wata-
nabe et al. (2000 [in this issue]), we report an MLS of
1.67 ( ) for waist-to-hip ratio (WHR) at 75.0Pp .0028
cM in QTL analysis of unaffected individuals. Also,
Hager et al. (1998) have reported an MLS of 4.85 for
BMI, at the marker D10S197 (47.3 cM on our map) in
a collection of French families. This result coincides
with a more proximal peak of 0.64 at 54.5 cM on
chromosome 10.
Pratley et al. (1998) reported a multipoint MLS of
2.99 for fasting glucose near the marker D22S270 on
chromosome 22, which was their best result for the trait.
Also, Hanis et al. (1996) found an MLS of 0.61 for
diabetes, at D22S270. This marker is ∼2 cM telomeric
to D22S423 (on the basis of the Whitehead Institute for
Biomedical Research/MIT Center for Genome Research
map), the marker that gave our strongest association
result.
At present, we are undertaking a number of differ-
ent strategies to positionally clone genes in areas of in-
terest. Our focus is on chromosome 22, near the marker
D22S423, and on chromosome 20, at the 69.5 cM peak.
We are typing additional markers in both these regions.
We see microsatellite marker-marker disequilibrium on
chromosome 20, at distances of !1 cM (authors’ un-
published data). Further interaction analyses are being
conducted by use of both GENEHUNTER PLUS (Cox
et al. 1999) and SIBLINK (Hauser et al. 1996). We will
carry out multivariate analyses in regions with overlap-
ping results and have generated phenotype comparisons
between apparently linked and unlinked families (au-
thors’ unpublished data). Finally, we and others have
embarked on a collaboration to map type 2 diabe-
tes–susceptibility genes by combining data sets and in-
tegrating maps (Boehnke et al. 1998).
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